Phase 4 Clinical Trial Primed For Stage 2 After Submission Of Interim Report To The FDA

KUALA LUMPUR, 24 December 2020 – HWGB Biotech Sdn Bhd (“HWGB Biotech”), a wholly owned subsidiary of Ho Wah Genting Berhad (“HWGB” or the “Company”) (Bursa Stock Code: 9601), announced E-MO Biology Inc.’s Interim Report of COVID-19 Vaccine Phase 4 Clinical Trial had been successfully submitted to the US Food and Drug Administration (“FDA”) Clinical Trial Gov System on the 23 December 2020 and the approval is expected to be received within the next few working days. HWGB’s joint venture partner, US-based E-MO Biology Inc. (“EBI”), completed the first stage study of Phase 4 clinical trial and is looking for the commencement to the next step of the expanded trial.

The review of the Interim Report by the FDA is on-going for EBI progression to provide a vaccine that will appeal to the public for COVID-19 prevention. By gaining the FDA approval, EBI will be able to embark on to a larger group study with an additional 275 Subjects, which will be stratified by age and race or ethnicity. The breakthrough was announced when the first stage of the study showed that 100% of the Subjects produced an immune response that recognized protein (RdRp) of both poliovirus and SARS-Cov-2 in their blood samples after vaccination.

Managing Director of EBI, Dr. Xie QiYi, said: “We intend to expand the study cohort to a total of 300 Subjects after the success on the pioneering 25 Subjects enrolled. No adverse effects were reported by the enrolled Subjects which proven that we are heading in the right direction and to continue this study on a larger and more diverse group”.

Ho Wah Genting Berhad (“HWGB” or the “Company”) is principally engaged in investment holdings and the provision of management services to its subsidiaries. The Company had on 30 June 2020 diversified its existing businesses to include healthcare-related industry which mainly involved in Health Supplement, Biotechnology and Health Technology. In addition, the Company and its subsidiaries (“HWGB Group” or the “Group”) are also engaging in the businesses of Investment holdings; manufacturing of wires and cables and moulded power supply cord sets and cable assemblies for electrical and electronic devices and equipment; Trading of wires and cables; and travel agent and tour related services.

HWGB Biotech Sdn Bhd, was incorporated on 18 June 2012 under the Companies Act, 1965 under the former name of HWG Consortium Sdn Bhd and changed to its current name on 22 May 2020. HWGB Biotech is principally involved in the distribution of all kinds of biotechnology products, bioinformatics diagnostic tools, all medical engineering equipment along with software developments and tools as well as to patent all original products and by-products, technologies and software developed or sourced by the company.

For more information about HWGB Biotech, follow us on https://hwgbbiotech.com, http://subscription.hwgbbiotech.com, Facebook, LinkedIn, and Telegram to view the latest updates about our company ventures in the healthcare industry.

Please refer to the US Food and Drug Administration website for more information on EBI’s Phase IV clinical study: https://www.clinicaltrials.gov/ct2/show/NCT04639375

E-Mo Biology Inc (“EBI”) was incorporated in the state of California in the United States of America on 24 May 2020. It is principally involved in conducting biology research and development activities and is the sponsor of a study which indicates booster polio vaccine to reduce Covid-19 SARS-COV-2 infection and severity.

EBI is founded by Dr. Xie QiYi, who serves as its Managing Director of EBI. He has over 30 years of experience in areas of public health and infection disease control. He was also involved in the development of medical and diagnostic devices, with focus on Quality, Regulatory and Clinical Affairs for quality systems.